Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: Results of a united states case-control study

Clara N Curiel, Tamar Nijsten, Maria L. Gomez, Loes M. Hollestein, Michael B. Atkins, Robert S. Stern

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Experimental and observational studies continue to demonstrate conflicting results regarding the role of several commonly used drugs as melanoma chemopreventive agents. This case-control study was designed to assess the associations between cutaneous melanoma (CM) and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) and statins in current users. A total of 400 CM and 600 eligible age- and gender-matched community-based controls were prospectively recruited and interviewed. We assessed participants demographic characteristics, CM risk factors, and current and previous use of medications. Multivariable conditional logistic regression models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between NSAIDs and/or aspirin (ASA), statin exposure, and CM risk. Half of the subjects were men (mean age 60 years). After adjusting for confounders, use of any type of NSAIDs for more than 5 years significantly reduced the risk of melanoma development compared with the low-exposure group (adjusted OR=0.57; 95% CI=0.43-0.77). Subgroup analyses showed that the observed risk reduction was primarily driven by continuous ASA use (>5 years adjusted OR=0.51, 95% CI-0.35-0.75). No significant protective effect was observed with statin exposure (OR=0.97, 95% CI=0.73-1.29). Long-term use of NSAIDs, especially ASA, is associated with a significantly decreased risk of CM development. Clinical intervention studies are warranted to further investigate the potential role of ASA and other NSAIDs as chemopreventive agents for CM.

Original languageEnglish (US)
Pages (from-to)1460-1468
Number of pages9
JournalJournal of Investigative Dermatology
Volume131
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Case-Control Studies
Melanoma
Anti-Inflammatory Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Skin
Pharmaceutical Preparations
Odds Ratio
Confidence Intervals
Logistic Models
Aspirin
Logistics
Risk Reduction Behavior
Observational Studies
Demography

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma : Results of a united states case-control study. / Curiel, Clara N; Nijsten, Tamar; Gomez, Maria L.; Hollestein, Loes M.; Atkins, Michael B.; Stern, Robert S.

In: Journal of Investigative Dermatology, Vol. 131, No. 7, 07.2011, p. 1460-1468.

Research output: Contribution to journalArticle

Curiel, Clara N ; Nijsten, Tamar ; Gomez, Maria L. ; Hollestein, Loes M. ; Atkins, Michael B. ; Stern, Robert S. / Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma : Results of a united states case-control study. In: Journal of Investigative Dermatology. 2011 ; Vol. 131, No. 7. pp. 1460-1468.
@article{d86775263c55452eaf22b38a69cac151,
title = "Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: Results of a united states case-control study",
abstract = "Experimental and observational studies continue to demonstrate conflicting results regarding the role of several commonly used drugs as melanoma chemopreventive agents. This case-control study was designed to assess the associations between cutaneous melanoma (CM) and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) and statins in current users. A total of 400 CM and 600 eligible age- and gender-matched community-based controls were prospectively recruited and interviewed. We assessed participants demographic characteristics, CM risk factors, and current and previous use of medications. Multivariable conditional logistic regression models were used to estimate adjusted odds ratios (ORs) and 95{\%} confidence intervals (CIs) for associations between NSAIDs and/or aspirin (ASA), statin exposure, and CM risk. Half of the subjects were men (mean age 60 years). After adjusting for confounders, use of any type of NSAIDs for more than 5 years significantly reduced the risk of melanoma development compared with the low-exposure group (adjusted OR=0.57; 95{\%} CI=0.43-0.77). Subgroup analyses showed that the observed risk reduction was primarily driven by continuous ASA use (>5 years adjusted OR=0.51, 95{\%} CI-0.35-0.75). No significant protective effect was observed with statin exposure (OR=0.97, 95{\%} CI=0.73-1.29). Long-term use of NSAIDs, especially ASA, is associated with a significantly decreased risk of CM development. Clinical intervention studies are warranted to further investigate the potential role of ASA and other NSAIDs as chemopreventive agents for CM.",
author = "Curiel, {Clara N} and Tamar Nijsten and Gomez, {Maria L.} and Hollestein, {Loes M.} and Atkins, {Michael B.} and Stern, {Robert S.}",
year = "2011",
month = "7",
doi = "10.1038/jid.2011.58",
language = "English (US)",
volume = "131",
pages = "1460--1468",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma

T2 - Results of a united states case-control study

AU - Curiel, Clara N

AU - Nijsten, Tamar

AU - Gomez, Maria L.

AU - Hollestein, Loes M.

AU - Atkins, Michael B.

AU - Stern, Robert S.

PY - 2011/7

Y1 - 2011/7

N2 - Experimental and observational studies continue to demonstrate conflicting results regarding the role of several commonly used drugs as melanoma chemopreventive agents. This case-control study was designed to assess the associations between cutaneous melanoma (CM) and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) and statins in current users. A total of 400 CM and 600 eligible age- and gender-matched community-based controls were prospectively recruited and interviewed. We assessed participants demographic characteristics, CM risk factors, and current and previous use of medications. Multivariable conditional logistic regression models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between NSAIDs and/or aspirin (ASA), statin exposure, and CM risk. Half of the subjects were men (mean age 60 years). After adjusting for confounders, use of any type of NSAIDs for more than 5 years significantly reduced the risk of melanoma development compared with the low-exposure group (adjusted OR=0.57; 95% CI=0.43-0.77). Subgroup analyses showed that the observed risk reduction was primarily driven by continuous ASA use (>5 years adjusted OR=0.51, 95% CI-0.35-0.75). No significant protective effect was observed with statin exposure (OR=0.97, 95% CI=0.73-1.29). Long-term use of NSAIDs, especially ASA, is associated with a significantly decreased risk of CM development. Clinical intervention studies are warranted to further investigate the potential role of ASA and other NSAIDs as chemopreventive agents for CM.

AB - Experimental and observational studies continue to demonstrate conflicting results regarding the role of several commonly used drugs as melanoma chemopreventive agents. This case-control study was designed to assess the associations between cutaneous melanoma (CM) and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) and statins in current users. A total of 400 CM and 600 eligible age- and gender-matched community-based controls were prospectively recruited and interviewed. We assessed participants demographic characteristics, CM risk factors, and current and previous use of medications. Multivariable conditional logistic regression models were used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for associations between NSAIDs and/or aspirin (ASA), statin exposure, and CM risk. Half of the subjects were men (mean age 60 years). After adjusting for confounders, use of any type of NSAIDs for more than 5 years significantly reduced the risk of melanoma development compared with the low-exposure group (adjusted OR=0.57; 95% CI=0.43-0.77). Subgroup analyses showed that the observed risk reduction was primarily driven by continuous ASA use (>5 years adjusted OR=0.51, 95% CI-0.35-0.75). No significant protective effect was observed with statin exposure (OR=0.97, 95% CI=0.73-1.29). Long-term use of NSAIDs, especially ASA, is associated with a significantly decreased risk of CM development. Clinical intervention studies are warranted to further investigate the potential role of ASA and other NSAIDs as chemopreventive agents for CM.

UR - http://www.scopus.com/inward/record.url?scp=79958853173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958853173&partnerID=8YFLogxK

U2 - 10.1038/jid.2011.58

DO - 10.1038/jid.2011.58

M3 - Article

C2 - 21390049

AN - SCOPUS:79958853173

VL - 131

SP - 1460

EP - 1468

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 7

ER -